Literature DB >> 7350861

Marrow aplasia and sulindac.

J L Miller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7350861     DOI： 10.7326/0003-4819-92-1-129_1

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  6 in total

1.  Reversible bone marrow aplasia induced by naproxen.

Authors:  S M Sanal; M Gur-Lavi
Journal:  Ann Hematol       Date:  1992-07       Impact factor: 3.673

2.  Aplastic anaemia associated with a non-steroidal anti-inflammatory drug: relapse after exposure to another such drug.

Authors:  R Andrews; N Russell
Journal:  BMJ       Date:  1990-07-07

Review 3.  Screening pharmaceuticals for possible carcinogenic effects: initial positive results for drugs not previously screened.

Authors:  Gary D Friedman; Natalia Udaltsova; James Chan; Charles P Quesenberry; Laurel A Habel
Journal:  Cancer Causes Control       Date:  2009-12       Impact factor: 2.506

4.  Acute pancreatitis associated with long-term sulindac therapy.

Authors:  D J Zygmunt; H J Williams; S R Bienz
Journal:  West J Med       Date:  1986-04

5.  Thrombocytopenia secondary to sulindac therapy.

Authors:  A M Shojania; S D Rusen
Journal:  Can Med Assoc J       Date:  1981-12-15       Impact factor: 8.262

Review 6.  Haematological effects of non-narcotic analgesics.

Authors:  P A Miescher; W Pola
Journal:  Drugs       Date:  1986       Impact factor: 9.546
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.